Selardsdi is indicated for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis in adults and ...

Teva and Alvotech announced that the U.S. Food and Drug Administration (FDA) approved SELARSDI (ustekinumab-aekn) injection as ...

YESINTEK will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

Yesintek is available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

It will be available in the same formulations as Stelara, including 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial. Shreehas Tambe, CEO & Managing Director of Biocon ...

as a fully interchangeable biosimilar to Stelara (ustekinumab). Selarsdi’s indications include adult and pediatric psoriatic arthritis (PsA) and plaque psoriasis, as well as Crohn disease and ...

“Interchangeability of SELARSDI with Stelara will further enable increased ... Approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for ...

Approved presentations of SELARSDI are 45 mg/0.5 mL and 90 mg/mL in a single ... host cell line and process used in the production of Stelara®. Biologics License Applications (BLAs) for three ...